Acambis (Cambridge, UK, www.acambis.com) and Bavarian Nordic (Kvistg?rd, Denmark, www.bavarian-nordic.com) have reached a global settlement ending the legal disputes between the two companies on matters relating to smallpox vaccines based on the modified vaccinia ankara (MVA) virus.
Acambis (Cambridge, UK, www.acambis.com) and Bavarian Nordic (Kvistgård, Denmark, www.bavarian-nordic.com) have reached a global settlement ending the legal disputes between the two companies on matters relating to smallpox vaccines based on the modified vaccinia ankara (MVA) virus. Under the agreement, Bavarian Nordic will grant a license to some of its MVA patents in return for making an undisclosed upfront payment from Acambis.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.